GTS Securities LLC cut its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 75.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 501 shares of the company's stock after selling 1,531 shares during the period. GTS Securities LLC's holdings in argenx were worth $308,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. FMR LLC grew its position in shares of argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after acquiring an additional 824,750 shares during the period. Capital World Investors grew its position in shares of argenx by 5.1% during the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after acquiring an additional 86,687 shares during the period. RTW Investments LP grew its position in shares of argenx by 2.9% during the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock valued at $414,201,000 after acquiring an additional 19,067 shares during the period. Clearbridge Investments LLC grew its position in shares of argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock valued at $387,344,000 after acquiring an additional 40,330 shares during the period. Finally, Jennison Associates LLC grew its position in shares of argenx by 27.0% during the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock valued at $185,821,000 after acquiring an additional 64,183 shares during the period. Institutional investors own 60.32% of the company's stock.
argenx Stock Down 0.7%
argenx stock traded down $4.21 during midday trading on Friday, reaching $576.74. The stock had a trading volume of 350,163 shares, compared to its average volume of 323,511. argenx SE has a 52-week low of $361.26 and a 52-week high of $678.21. The firm has a market cap of $35.22 billion, a price-to-earnings ratio of -655.39 and a beta of 0.57. The company has a fifty day moving average of $586.57 and a 200 day moving average of $612.43.
argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. Equities research analysts predict that argenx SE will post 3.13 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on ARGX. Wells Fargo & Company upped their target price on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 target price on shares of argenx in a report on Tuesday, April 8th. Wedbush reaffirmed an "outperform" rating and issued a $715.00 target price on shares of argenx in a report on Friday, April 11th. William Blair reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Finally, Baird R W raised shares of argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, argenx currently has an average rating of "Buy" and a consensus price target of $709.18.
Read Our Latest Research Report on argenx
argenx Company Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Stories
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
